Emerald Advisers’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
|
|||||
|
2023
Q2 | $32.3M | Buy |
|
|||||
|
2023
Q1 | $28.6M | Sell |
|
|||||
|
2022
Q4 | $25.8M | Buy |
|
|||||
|
2022
Q3 | $13.5M | Buy |
|
|||||
|
2022
Q2 | $8.7M | Buy |
|
|||||
|
2022
Q1 | $8.87M | Buy |
|
|||||
|
2021
Q4 | $4.72M | Sell |
|
|||||
|
2021
Q3 | $27.8M | Buy |
|
|||||
|
2021
Q2 | $34.9M | Sell |
|
|||||
|
2021
Q1 | $26.1M | Buy |
|
|||||
|
2020
Q3 | – | Sell |
|
|||||
|
2020
Q2 | $9.9M | Sell |
|
|||||
|
2020
Q1 | $16.5M | Buy |
|
|||||
|
2019
Q4 | $20.9M | Sell |
|
|||||
|
2019
Q3 | $22.7M | Sell |
|
|||||
|
2019
Q2 | $36.5M | Sell |
|
|||||
|
2019
Q1 | $33.5M | Sell |
|
|||||
|
2018
Q4 | $26.4M | Sell |
|
|||||
|
2018
Q3 | $38.7M | Sell |
|
|||||
|
2018
Q2 | $19.1M | Buy |
|
|||||
|
2018
Q1 | $10.1M | Sell |
|
|||||
|
2017
Q4 | $15.9M | Sell |
|
|||||
|
2017
Q3 | $17.7M | Buy |
|
|||||
|
2017
Q2 | $12.9M | Buy |
|
|||||
|
2017
Q1 | $8.38M | Buy |
|
|||||
|
2016
Q4 | $7.14M | Buy |
|
|||||
|
2016
Q3 | $6.35M | Buy |
|
|||||
|
2016
Q2 | $3.31M | Buy |
|